Status:
COMPLETED
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Lead Sponsor:
Helsinn Therapeutics (U.S.), Inc
Conditions:
Cancer Cachexia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated...
Eligibility Criteria
Inclusion
- Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer.
- Involuntary loss of body weight of ≥ 5 % within the past 6 months
Exclusion
- Presently hospitalized or in a nursing care facility.
- Inability to increase food intake from secondary causes.
- Liver disease
- If female-pregnant, breast-feeding or of childbearing potential.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00219817
Start Date
June 1 2005
End Date
October 1 2006
Last Update
September 2 2013
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
California Cancer Care Center
Greenbrae, California, United States, 94904
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
3
Columbia University Medical Center
New York, New York, United States, 10032
4
University of Texas Medical Branch at Galveston
Galveston, Texas, United States, 77555